West Pharmaceutical Services (WST) Stock Buyback History
TTM buyback yield 1.65% · Shareholder yield (TTM) 1.65%.
TTM buyback yield
1.65%
Shareholder yield (TTM)
1.65%
5Y share count change
-4.1%
TTM buyback spend
$298.40M
SBC coverage (TTM)
10.25x
YoY change in spend
-76.4%
5Y CAGR of spend
+2.0%
Peak year (2024)
$566.60M
Cumulative spend
$2.12B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- West Pharmaceutical Services (WST) repurchased about $298.40M of stock over the trailing twelve months.
- Diluted share count is down 4.1% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 10.25× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +2.0% per year over the latest 5-year window.
- TTM repurchases used about 75% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $134.00M | $23.80M | $110.20M | 0.07B | -1.4% | 0.67% |
| 2024 | $566.60M | $18.70M | $547.90M | 0.07B | -2.1% | 2.37% |
| 2023 | $451.20M | $23.30M | $427.90M | 0.08B | -0.7% | 1.73% |
| 2022 | $222.20M | $23.70M | $198.50M | 0.08B | -0.7% | 1.27% |
| 2021 | $151.90M | $37.50M | $114.40M | 0.08B | 0.7% | 0.43% |
| 2020 | $121.40M | $34.00M | $87.40M | 0.08B | 0.5% | 0.58% |
| 2019 | $85.30M | $24.40M | $60.90M | 0.08B | 0.0% | 0.77% |
| 2018 | $70.80M | $15.10M | $55.70M | 0.08B | -0.5% | 0.98% |
| 2017 | $74.40M | $16.10M | $58.30M | 0.08B | 1.1% | 1.02% |
| 2016 | $55.90M | $19.50M | $36.40M | 0.07B | 1.6% | 0.90% |
| 2015 | $5.60M | $29.60M | −$24.00M | 0.07B | 1.4% | 0.13% |
| 2014 | $4.10M | $18.60M | −$14.50M | 0.07B | 2.0% | 0.11% |
| 2013 | $5.20M | $21.20M | −$16.00M | 0.07B | -0.6% | 0.15% |
| 2012 | $4.70M | $15.50M | −$10.80M | 0.07B | -3.0% | 0.25% |
| 2011 | $3.50M | $8.40M | −$4.90M | 0.07B | 0.8% | 0.27% |
| 2010 | $2.10M | $7.80M | −$5.70M | 0.07B | 1.1% | 0.15% |
| 2009 | $1.30M | $7.50M | −$6.20M | 0.07B | 0.6% | 0.10% |
| 2008 | $5.20M | $6.40M | −$1.20M | 0.07B | -0.3% | 0.42% |
| 2007 | $43.00M | $0.00 | $43.00M | 0.07B | 7.7% | 3.29% |
| 2006 | $0.00 | $0.00 | $0.00 | 0.07B | 3.4% | — |
| 2005 | $100.00K | $0.00 | $100.00K | 0.07B | 5.5% | 0.01% |
| 2004 | $100.00K | $0.00 | $100.00K | 0.06B | 5.8% | 0.01% |
| 2003 | $0.00 | $0.00 | $0.00 | 0.06B | 0.7% | — |
| 2002 | $100.00K | $0.00 | $100.00K | 0.06B | 0.7% | 0.03% |
| 2001 | $100.00K | $0.00 | $100.00K | 0.06B | -0.4% | 0.03% |
| 2000 | $10.80M | $0.00 | $10.80M | 0.06B | -4.2% | — |
| 1999 | $18.10M | $0.00 | $18.10M | 0.06B | -8.8% | — |
| 1998 | $60.40M | $0.00 | $60.40M | 0.07B | -0.4% | — |
| 1997 | $0.00 | $0.00 | $0.00 | 0.07B | 0.9% | — |
| 1996 | $0.00 | $0.00 | $0.00 | 0.07B | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1992 | $3.30M | $0.00 | $3.30M | — | — | — |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1990 | $11.30M | $0.00 | $11.30M | — | — | — |
| 1989 | $5.30M | $0.00 | $5.30M | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for West Pharmaceutical Services (WST) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for West Pharmaceutical Services (WST)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for West Pharmaceutical Services (WST)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $134.00M | -76.4% | -$432.60M | ||
| 2024 | $566.60M | +25.6% | +$115.40M | ||
| 2023 | $451.20M | +103.1% | +$229.00M | ||
| 2022 | $222.20M | +46.3% | +$70.30M | ||
| 2021 | $151.90M | +25.1% | +$30.50M | ||
| 2020 | $121.40M | +42.3% | +$36.10M | ||
| 2019 | $85.30M | +20.5% | +$14.50M | ||
| 2018 | $70.80M | -4.8% | -$3.60M | ||
| 2017 | $74.40M | +33.1% | +$18.50M | ||
| 2016 | $55.90M | +898.2% | +$50.30M | ||
| 2015 | $5.60M | +36.6% | +$1.50M | ||
| 2014 | $4.10M | -21.2% | -$1.10M | ||
| 2013 | $5.20M | +10.6% | +$500,000 | ||
| 2012 | $4.70M | +34.3% | +$1.20M | ||
| 2011 | $3.50M | +66.7% | +$1.40M | ||
| 2010 | $2.10M | +61.5% | +$800,000 | ||
| 2009 | $1.30M | -75.0% | -$3.90M | ||
| 2008 | $5.20M | -87.9% | -$37.80M | ||
| 2007 | $43.00M | — | +$43.00M | ||
| 2006 | $0 | -100.0% | -$100,000 | ||
| 2005 | $100,000 | 0.0% | $0 | ||
| 2004 | $100,000 | — | +$100,000 | ||
| 2003 | $0 | -100.0% | -$100,000 | ||
| 2002 | $100,000 | 0.0% | $0 | ||
| 2001 | $100,000 | -99.1% | -$10.70M | ||
| 2000 | $10.80M | -40.3% | -$7.30M | ||
| 1999 | $18.10M | -70.0% | -$42.30M | ||
| 1998 | $60.40M | — | +$60.40M | ||
| 1997 | $0 | — | $0 | ||
| 1996 | $0 | — | $0 | ||
| 1995 | $0 | — | $0 | ||
| 1994 | $0 | — | $0 | ||
| 1993 | $0 | -100.0% | -$3.30M | ||
| 1992 | $3.30M | — | +$3.30M | ||
| 1991 | $0 | -100.0% | -$11.30M | ||
| 1990 | $11.30M | +113.2% | +$6.00M | ||
| 1989 | $5.30M | — | — |
In 2025, West Pharmaceutical Services (WST) buyback spend totalled $134.00M – plunged 76.4% year-over-year.
Over 2020–2025 (5 years), West Pharmaceutical Services buyback spend expanded at a +2.0% compound annual rate, with the latest reading among the more recent periods of the dataset.
West Pharmaceutical Services buyback spend plunged from $566.60M in 2024 to $134.00M in 2025, a 76.4% drawdown.
2024 marks the peak buyback spend at $566.60M, with the historical low of $0 recorded in 1991.
Among 8 Healthcare peers, West Pharmaceutical Services (WST) ranks 8th; the peer median for buyback spend is $2.75B.
West Pharmaceutical Services Buyback Spend 2025: $134.00M
West Pharmaceutical Services buyback spend in 2025 was $134.00M, plunged 76.4% below 2024.
West Pharmaceutical Services Buyback Spend 2024: $566.60M
West Pharmaceutical Services buyback spend in 2024 was $566.60M, grew 25.6% from 2023. This figure represents the highest annual value in the available history.
West Pharmaceutical Services Buyback Spend 2023: $451.20M
West Pharmaceutical Services buyback spend in 2023 was $451.20M, surged 103.1% from 2022.
West Pharmaceutical Services Buyback Spend 2022: $222.20M
West Pharmaceutical Services buyback spend in 2022 was $222.20M, surged 46.3% from 2021.
West Pharmaceutical Services Buyback Spend 2021: $151.90M
West Pharmaceutical Services buyback spend in 2021 was $151.90M.
See more financial history for West Pharmaceutical Services (WST).
Sector peers by buyback spend
Companies in the same sector as West Pharmaceutical Services, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 10.25×.
Capital allocation mix
How West Pharmaceutical Services splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $396.20M (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from West Pharmaceutical Services's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does West Pharmaceutical Services buy back its own stock?
Yes, West Pharmaceutical Services (WST) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does West Pharmaceutical Services spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $298.40M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is West Pharmaceutical Services's buyback yield?
TTM buyback yield is about 1.65% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is West Pharmaceutical Services's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 1.65% combined (TTM-based where available).
Is West Pharmaceutical Services diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has West Pharmaceutical Services's share count changed?
Diluted weighted average shares changed by about -4.1% over roughly five fiscal years (annual income statement data).
What is West Pharmaceutical Services's buyback spend?
Latest reported buyback spend for West Pharmaceutical Services (WST) is $298.40M (period ending March 31, 2026).
How has West Pharmaceutical Services buyback spend changed year-over-year?
West Pharmaceutical Services (WST) buyback spend changed -76.4% year-over-year on the latest annual filing.
What is the long-term growth rate of West Pharmaceutical Services buyback spend?
West Pharmaceutical Services (WST) buyback spend compound annual growth rate is +2.0% over the most recent 5 years available.
When did West Pharmaceutical Services buyback spend hit its highest annual value?
West Pharmaceutical Services buyback spend reached its highest annual value of $566.60M in 2024.
What was West Pharmaceutical Services buyback spend in 2024?
West Pharmaceutical Services (WST) buyback spend in 2024 was $566.60M.
What was West Pharmaceutical Services buyback spend in 2025?
West Pharmaceutical Services (WST) buyback spend in 2025 was $134.00M.
Explore more
WST Overview
Company profile, financial tools, and key metrics
WST Revenue Counter
Earns $102.12 every second. See per minute, hour, and day.
WST Earnings Counter
Earns $17.21 per second net profit. See per minute, hour, and day.
WST Economic Scale
Exceeds Belize's GDP. Compare with world economies.
WST What If Invested
What if you had invested $1,000? See historical returns from any date.
WST How It Makes Money
Discover visual breakdown of $3.22B in revenue — where it comes from and where it goes.
WST Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
WST Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
WST Daily Price Character
Steady · 44.8% historical win rate (green days). Streaks & record days.
WST Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.
WST Dividend Profile
Yield: 0.28%. Safety: 6/8. See full history.
WST Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
WST Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
WST Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
WST Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.